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Objective: Because extensively drug-resistant tuberculosis has emerged, adequate control of drug-resistant
tuberculosis has become increasingly important. We report on our experience using liberal adjuvant resectional
surgery as part of aggressive treatment for multidrug-resistant tuberculosis.
Methods:We retrospectively reviewed the records of 56 consecutive patients who underwent pulmonary resec-
tions for multidrug-resistant tuberculosis between January 2000 and June 2007. There were 42 males and 14 fe-
males (mean age, 46 years; range, 22-64 years). Isolates were resistant to a mean of 5.6 drugs (range, 2-10 drugs).
Multi-drug regimens employing 3 to 7 drugs (mean, 4.6 drugs) were initiated in all patients. Indications for sur-
gery were a high risk of relapse for 37 patients, persistent positive sputum for 18, and 1 with associated empyema.
Results: The 56 patients underwent 61 pulmonary resections (3 completion pneumonectomies, 19 pneumonec-
tomies, 33 lobectomies, and 6 segmentectomies). Bronchial stumps were reinforced with muscle flaps in 54
resections. Operative mortality and morbidity rates were 0% and 16%, respectively. All patients attained
postoperative sputum-negative status. Relapse occurred in 5 patients; 3 were converted by a second resection,
and 1 responded to augmentation of chemotherapy. Late death occurred for 2 patients without evidence of relapse.
Among 54 survivors, 53 (98%) were considered cured.
Conclusion: Surgical treatment that complements medical treatment has proved safe and efficacious for patients
with multidrug-resistant tuberculosis. In an era with extensively drug-resistant tuberculosis, an aggressive treat-
ment approach to multidrug-resistant tuberculosis continues to be justified until a panacea for this refractory
disease is available.The emergence of multidrug-resistant tuberculosis—defined
as resistance to at least isoniazid and rifampicin1—has ad-
versely affected the global battle against tuberculosis.2
Now that the existence of extensively drug-resistant tubercu-
losis, a very serious form of multidrug-resistant tuberculosis,
has been recognized,3 adequate control of drug-resistant
tuberculosis is becoming increasingly important. Multi-
drug-resistant tuberculosis has disseminated world-wide,
and Japan is no exception.4 As one of the specialized centers
for multidrug-resistant tuberculosis in Japan, our hospital
has received a number of referrals for treatment of patients
with multidrug-resistant tuberculosis. To eliminate a risk
of further treatment failure, we have been treating these pa-
tients in an aggressive manner. We have performed resec-
tional surgeries for patients, whenever feasible, in order to
enhance the efficacy of their medical treatments. Surgical
treatment has been used not only to achieve sputum conver-
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our most recent experience with aggressive treatments of pa-
tients with multidrug-resistant tuberculosis, with an empha-
sis on continued liberal use of adjuvant resectional surgery
and on reduction of postoperative complications.
PATIENTS AND METHODS
We retrospectively reviewed the records of 56 consecutive patients who
underwent pulmonary resections for multidrug-resistant tuberculosis at
Fukujuji Hospital between January 2000 and June 2007. The study was
approved, with a waiver for patient consent, by the institutional review
board on human research at Fukujuji Hospital.
There were 42 men (75%) and 14 women (25%), including 8 foreigners:
4 Chinese, 2 Filipinos, 1 Nepalese, and 1 Nigerian. Ages at the time of sur-
gery ranged from 22 to 64 years (mean, 46 years). None of the patients was
HIV-positive. The average body mass index at the time of admission was
21.0 (range, 14.4 to 29.2). Seventeen patients had diabetes. All but 3 patients
had received anti-tuberculosis chemotherapy at their referral hospitals, and
had been transferred to our hospital to seek specialized care for multidrug-
resistant tuberculosis. Sputum smears and sputum cultures were performed
upon admission. Drug susceptibility testing was routinely performed on
positive cultures in our laboratory, not only for first-line drugs, but also
for second-line drugs and levofloxacin. Bronchoscopy was done for some
cases to rule out contralateral disease and/or co-existing malignancies.
At the time of admission, patients’ isolates were resistant to a mean of 5.6
drugs (range, 2 to 10 drugs), including isoniazid and rifampicin. Multidrug
regimens employing a mean of 4.6 drugs (range, 3 to 7 drugs) were initiated
in all patients. Treatment regimens were individualized based upon drug
susceptibility test results, and comprised as many effective drugs as possible
to prevent multidrug-resistant bacilli from acquiring further drug resistance.
Fluoroquinolones were included in the regimens of 49 patients (88%). Lev-
ofloxacin, gatifloxacin, sparfloxacin and ciprofloxacin were used for 26rgery c November 2009
Shiraishi et al General Thoracic Surgery
G
T
Spatients, 17 patients, 5 patients and 1 patient, respectively. Other drugs em-
ployed included ethambutol, streptomycin, kanamycin, enviomycin, cyclo-
serine, ethionamide, para-aminosalicylic acid, pyrazinamide, sultamicillin
tosilate and thioacetazone.
After keeping patients under chemotherapy for at least 3 months, we re-
viewed their sputum smear and culture results and radiographic appear-
ances. Resection of cavitary lesions or destroyed lobes was considered for
those patients who had persistently positive sputum, despite chemotherapy.
Among patients who achieved sputum conversion in response to chemo-
therapy, surgery was considered for those at high risk of relapse based
upon drug resistance patterns and/or radiographic findings, ie, patients
with a higher number of resistant drugs, the bigger size of cavity, and dia-
betes. Preoperative studies included a chest roentgenogram, computed to-
mographic scan of the chest, pulmonary function tests, arterial blood gas
analysis, and a quantitative perfusion scan. Emphasis was placed upon as-
certaining if patients had sufficient pulmonary reserve to tolerate pulmonary
resection and if they had lesions that were predominantly localized to one
lung. We accepted scattered nodular lesions or limited cavitary lesions in
the lungs on the opposite side on the presumption that those lesions could
be managed by postoperative chemotherapy or staged bilateral resections.
Radiographic appearances of responsible lesions were cavities in 52 pa-
tients, nodular lesions in 2, and a destroyed lobe and empyema in 1 each.
Fifteen patients (27%) had their tuberculosis limited entirely to 1 side,
with the opposite side totally intact. Preoperative vital capacity ranged
from 1.6 to 5.78 L (mean, 3.29 L) and forced expiratory volume in 1 second
ranged from 0.62 to 4.56 L (mean, 2.56L). Indications for surgery included
persistent positive sputum for 18 patients (32%) and a high risk of relapse
for 37 patients (66%). For 1 patient (2%), surgery was performed because
he had an associated empyema.
Surgery was performed using the technique previously reported.5 We
usually performed a posterolateral thoracotomy. Late in this series, we
used an anterolateral thoracotomy for selected patients in whom dense pleu-
ral adhesions were not anticipated. The bronchus was divided and closed
with staples (n ¼ 57) or sutures (n ¼ 4). We routinely reinforced the bron-
chial stump with muscle flaps, except when we did segmentectomy. Our
preferred muscle was a latissimus dorsi. When the large residual space
was considerable, we employed limited thoracoplasty or a latissimus dorsi
muscle tent6 to reduce the space. All resected specimens were sent for path-
ological and bacteriological examinations.
After surgery, all patients were maintained on multidrug regimens, gen-
erally the same as their preoperative regimens, for 2 years after the time of
surgery or after the time of sputum conversion. Durations of postoperative
chemotherapy ranged from 6 to 84 months (median, 18 months). Follow-up
data were obtained from outpatient or hospital charts, or by direct contacts
with patients or relatives. Postsurgical follow-up was completed on Decem-
ber 31, 2008. Durations of follow-up ranged from 8 to 105 months (median,
39 months). Operative mortality included all deaths that were clearly related
to the operations, regardless of the postoperative interval. All cases of bron-
chopleural fistula or empyema that occurred subsequent to the date of sur-
gery were considered postoperative complications.
RESULTS
Fifty-six patients underwent 61 pulmonary resections.
Five patients had 2 resections, 2 had planned staged bilateral
resections for bilateral lesions, and 3 had a second resection
due to relapse. The procedures included completion pneu-
monectomy (n¼ 3), pneumonectomy (n¼ 19), bilobectomy
(n ¼ 1), lobectomy (n ¼ 32), and segmentectomy (n ¼ 6).
Surgical procedures were equally divided between the right
and left sides (Table 1). Operating times ranged from 120 to
635 minutes (mean, 293 minutes). The average intraopera-
tive blood loss was 297 mL (range, 10 to 1656 mL). Bron-The Journal of Thoracic and Cchial stumps were reinforced with muscle flaps in 54
resections. A latissimus dorsi muscle was used in 47 resec-
tions, an intercostal muscle in 5, and other extrathoracic
muscles in 2. A concomitant limited thoracoplasty was per-
formed in 8 resections and the latissimus dorsi muscle tent
was used in 1 resection. For 10 of the 37 patients (27%)
who underwent resections for the prevention of relapse, cul-
tures of the contents of their resected specimens yielded pos-
itive results.
There was no operative mortality. A total of 11 complica-
tions occurred in 10 patients (16%) (Table 2). Nine of these
10 patients had been operated on during the first 3 years of
this series. In the following 4 1/2 years, only an occult bron-
chopleural fistula occurred in 1 patient. This fistula was
a complication of a right completion pneumonectomy with
a pectoralis major muscle flap and thoracoplasty. It was
not associated with clinical symptoms, and it was success-
fully treated by chest tube thoracostomy.
All patients attained sputum-negative status after their
surgeries. Relapse of multidrug-resistant tuberculosis oc-
curred in 5 patients. Three were converted by a second resec-
tion, 1 responded to augmentation of chemotherapy and 1
remained positive. The first patient had a relapse around
the bronchial stump 21 months after a left upper lobectomy,
which resulted in a bronchopleural fistula with tuberculous
TABLE 1. Types of pulmonary resections in this series: Early (2000–
2002) and late (2003–2007)
Procedure 2000–2002 2003–2007
Right completion pneumonectomy 1 1(1y)
Right pneumonectomy 5 1
Right upper and middle lobectomy 1 0
Right upper lobectomy with segmentectomy* 4(1y) 3(1y,1z)
Right upper lobectomy 5 7(1y)
Right segmentectomy 1 0
Left completion pneumonectomy 0 1(1y)
Left pneumonectomy 6 7
Left upper lobectomy with segmentectomy* 1 0
Left upper lobectomy 5 6(1y)
Left lower lobectomy 1(1y) 0
Left segmentectomy 3 2(1y)
Total 33(2y) 28(6y,1z)
*Upper lobectomy with resection of superior segment of the lower lobe; The numbers
of resections ywith thoracoplasty or zwith muscle tent are shown in parentheses.
TABLE 2. Postoperative complications in this series: Early (2000–
2002) and late (2003–2007)
Postoperative complications
2000–2002
(n ¼ 33)
2003–2007
(n ¼ 28)
Bronchopleural fistula with empyema 2 0
Bronchopleural fistula (occult) 0 1
Space problem 5 0
Prolonged air leak 2 0
Chylothorax 1 0
Total 10 1ardiovascular Surgery c Volume 138, Number 5 1181
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Sempyema. He underwent an open window thoracostomy fol-
lowed by completion pneumonectomy. The second patient
had a relapse in the postlobectomy space 3 months after
a right upper lobectomy with segmentectomy. He was
treated by completion pneumonectomy following open
drainage. The third patient, status post right upper lobec-
tomy with segmentectomy 14 months prior, had a relapse
of cavities in the left lung. Because he had had his postoper-
ative chemotherapy terminated 2 months before that, he was
returned to a multidrug regimen and underwent a left upper
lobectomy. The fourth patient resumed having positive spu-
tum 4months after surgery while he was under postoperative
chemotherapy. He was successfully treated by augmentation
of a multidrug regimen. The fifth patient had a relapse
around the bronchial stump 5 months after a right pneumo-
nectomy. The bronchial stump was eroding, which resulted
in a bronchopleural fistula with tuberculous empyema. He
underwent an open window thoracostomy, but the left
lung was contaminated with multidrug-resistant tuberculo-
sis. He is the only patient who remains shedding positive
sputum and is under chemotherapy. Late death occurred
for 2 patients without evidence of relapse. Among 54 survi-
vors, 53 (98%) were considered cured.
DISCUSSION
Over the past 3 decades, the presence of multidrug-resis-
tant tuberculosis has been 1 of the major obstacles for the
global eradication of tuberculosis.2 To improve the efficacy
of medical treatment for multidrug-resistant strains, such in-
novations as fluoroquinolone-containing regimens have
been adopted.7,8 Recently, the world has entered an era of ex-
tensively drug-resistant tuberculosis, ie, multidrug-resistant
strains that have acquired additional drug resistance to any
fluoroquinolone and to at least 1 of the 3 injectable drugs:
capreomycin, kanamycin, and amikacin.3 The emergence
of extensively drug-resistant tuberculosis may be the result
of years of inadequate management of drug-resistant tuber-
culosis. In order to prevent creating another extensively
drug-resistant strain, it is of upmost importance that we
cure patients while they have ordinary multidrug-resistant
strains.
It is indisputable that the first-line treatment for multidrug-
resistant tuberculosis is medical treatment. The overall suc-
cess rate for multidrug-resistant tuberculosis treatment has
reached 62% based on a meta analysis of a variety of current
treatment regimens.9 However, much higher cure rates have
been achieved when a combination of medical and surgical
treatments is applied.10-14 In our study, the cure rate of 98%
with relatively long-term follow-up is fairly good compared
with results of other studies.10-14 Our surgically-treated pa-
tients comprised 2 types of patients: (1) patients who contin-
ued to have positive sputum despite chemotherapy and (2)
patients who had sputum converted, but were considered
at high risk of relapse. It is unquestionable that the primary1182 The Journal of Thoracic and Cardiovascular Sugoal of adjuvant resectional surgery is to achieve sputum
conversion for persistent sputum-positive patients. On the
other hand, since medical treatment of multidrug-resistant
tuberculosis has been making steady progress, and because
surgical treatment has been inherently associated with mor-
bidity, it is debatable whether or not resectional surgery
should be utilized liberally for the purpose of preventing re-
lapse in sputum-converted patients.
Since we commenced the use of fluoroquinolone-contain-
ing regimens, the efficacy of medical treatment in our pro-
gram has improved. In this study, 66% of the patients were
sputum-converted prior to surgery, primarily by using levo-
floxacin- or gatifloxacin-containing regimens. These results
are consistent with those in recently reported series.12-14
Sputum conversion, however, does not mean that patients
are free from active strains, especially when chemotherapy
has not been able to transform cavitary lesions into nodular
types. Bacteriologic examinations of our resected specimens
demonstrated that 27% of the preoperatively culture-negative
patients were still harboring viable bacilli in their target le-
sions. Therefore, with a view to eliminating the potential
risk of relapse, we think that resectional surgery continues
to be warranted for patients who have achieved sputum con-
version, but who remain with cavities or destroyed lungs.
Without achieving acceptably low operative morbidity
and mortality rates, we cannot justify the liberal use of resec-
tional surgery. In this study, the operative mortality was
zero, which was consistent with what has been reported in
other series.10-14 The morbidity rate was 16 %, which was
a mediocre result, but comparable to the rates in other stud-
ies.10-14 In our previous study, bronchopleural fistulas and
space problems were noticeable postoperative problems.5
As we gained more experience, we could prevent these com-
plications late in this series.
Concerning bronchopleural fistulas, the fistulas that we
encountered early in this series occurred late after surgery
and were associated with relapse. This fact confirmed to us
that postoperative chemotherapy should be vigorous enough
to control any remaining bacilli around the bronchial stump.
We continued to put a muscle flap on the bronchial stump
and to employ individualized multi-drug regimens through-
out the treatment period. We did not experience a clinically
evident bronchopleural fistula during the last 4 1/2 years of
this series.
In addition, space problems became preventable late in
this series. In our previous study, the use of a latissimus dorsi
muscle flap could not eliminate a risk of space problems.
These problems occurred mainly in patients who underwent
procedures that were more extensive than lobectomy, such
as bilobectomy or lobectomy with segmentectomy. The re-
maining lobes were inherently too small and too stiff to fill
the entire pleural space. For such cases, we found that we
had left the raw surface of the remaining lobes open to the
post-resectional space when we sewed the latissimus dorsirgery c November 2009
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technique for dealing with the residual space, either by oblit-
erating the space with concomitant limited thoracoplasty or
by covering the raw surface with the latissimus dorsi (muscle
tent).6 During the last 4 1/2 years of this series, we did not
encounter space problems in any patients.
Postoperative chemotherapy is as indispensable as pre-
operative chemotherapy. The purpose of resectional surgery
is to remove the main lesions that harbor numerous organ-
isms. This means that scattered nodular lesions and tiny cav-
ities may be left behind. In this study, approximately 3/4 of
patients had some degree of lesions in the lungs on the oppo-
site side. Hence, it is crucial to keep patients on multidrug
regimens for a sufficiently long period in order to hold the
bacilli at bay in these lesions. Our duration of postoperative
chemotherapy is 2 years, either when patients have positive
sputum at the time of surgery or when they have positive
specimen culture results. We may shorten the duration of
chemotherapy, provided that patients have achieved sputum
conversion prior to surgery and have negative specimen cul-
ture results. However, the optimal duration of postoperative
chemotherapy requires further investigation.
Our study includes several distinctive features. First, as we
are affiliated with the Japan Anti-Tuberculosis Association,
our institution is one of the most experienced centers for
the treatment of multidrug-resistant tuberculosis in Japan.
We have such a reliable laboratory that we can routinely
perform drug susceptibility testing on first- and second-
line drugs and levofloxacin. As we have all types of anti-
tuberculosis drugs on hand, we can create the best available
multi-drug regimens that are individualized for each patient.
Nevertheless, favorable results with adjuvant resectional
surgery have been reported not only from developed coun-
tries, but also from developing countries where medical
resources are limited.13,14
Second, we preferred to use gatifloxacin late in this series
in expectation of its potent efficacy against tuberculosis
bacilli.15 Gatifloxacin has, however, been currently with-
drawn from sale both in the United States and in Japan be-
cause of the increased risk of dysglycemia in humans.
This necessitates alternate, newer fluoroquinolones. As we
live in an era in which extensively drug-resistant tuberculo-
sis exists, multidrug-resistant tuberculosis should be con-
trolled by any means. An aggressive treatment approach to
multidrug-resistant tuberculosis continues to be justified un-
til a panacea for this refractory disease is available.
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Discussion
Dr Alain Chapelier (Suresnes, France). Dr Shiraishi and col-
leagues reported their updated experience of patients with
multidrug-resistant Mycobacterium tuberculosis (MDR-TB) who
underwent adjuvant resectional surgery with no mortality and
excellent outcome. Dr Shiraishi has to be congratulated for these
results in a technically challenging group of patients and for his
nice presentation.
Surgery was considered for the patients with persistent positive
sputum and the patients with a high risk of relapse because of resid-
ual cavitary lesions. Among this latter group, a positive bacterial
examination of specimen was observed in approximately one third
of patients who were preoperatively culture-negative, and this is
a strong argument for surgery.
In this series, resections were performedwith extended use of the
latissimus dorsi muscle flap to reinforce the bronchial stump, as it
has been also recommended by others. You outline a significant re-
duction of postoperative complications in the recent period of your
experience. No residual pleural space problem was observed in the
late period of your study.
I have 3 questions. My first question is related to the additional
thoracoplasty. In the situation of a large post-resection space after
an upper lobectomy, extended or not to the upper segment of the
lower lobe, would you now advocate it systematically?
Dr Shiraishi (Tokyo, Japan). Yes, I would. In our series, we
found that space problems often occurred after we performedrdiovascular Surgery c Volume 138, Number 5 1183
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Sa bilobectomy or lobectomy plus segmentectomy of the lower lobe.
To prevent the residual space, we have to close the residual space
by concomitant limited thoracoplasty or a muscle tent. I think the
important thing is that at first we put the latissimus dorsi just
onto the bronchial stump, but in that case we found that the raw sur-
face of the remaining lung was exposed to the pleural cavity and
might cause a minor leak and result in residual space. So I think
we have to remove some of the ribs to reduce the space and cover
the raw surface of the lung with muscle flap.
Dr Chapelier. My second question is concerning the patients
with bilateral lesions. Many of your patients had small nodular le-
sions in the contralateral lung at the time of preoperative assess-
ment. In 2 patients, however, you performed a planned staged
bilateral resection. Could you comment on your strategy for these
patients?
Dr Shiraishi. The best candidate for surgical therapy was the
patient who had limited lesions, for example, a cavity just in the
right upper lobe or left upper lobe, but some patients had cavities
in both lungs. In that case, if the patient had good pulmonary func-
tion and a cavity was just localized in both sides of the upper lobes,
we were able to remove both lesions, so we performed planned
staged bilateral resections. Also, if the cavity is very small (eg, 5
or 6 mm), maybe we can leave those lesions.
DrChapelier. Finally, your institution is clearly a referral center
for the treatment of MDR-TB in Japan, and you point out in the ar-
ticle the extreme importance of your laboratory to assess the effi-
cacy of all drugs preoperatively and postoperatively. Considering
the incidence of MDR-TB in the population of west European
countries, for example, the prevalence of newly diagnosed cases
is 1.4% in France with a stability during the last 10 years, and
with regard to the medical and surgical expertise required to reach
the results you reported today, would you recommend that this
combined treatment be done in only 1 or 2 centers in our countries?
Dr Shiraishi. I don’t understand your question.
Dr Chapelier.Do you think these difficult cases have to be done
in selected centers?
Dr Shiraishi. Oh, yes. Surgery should be done in very special-
ized and highly experienced centers.
Dr Chapelier. Thank you.
Dr Marvin Pomerantz (Aurora, Colo). I enjoyed your article.
Your results parallel our series published in the Journal of 180 re-
sections in 174 patients, which was in 2001. I have 2 questions.
Two of 3 of your pneumonectomies were on the left side. Every se-
ries I have ever read shows that if you do a pneumonectomy for tu-
berculosis, it is more often on the left side. Why is that?
Dr Shiraishi. Some groups have termed it ‘‘left lung syn-
drome’’ in such patients with tuberculosis. The left lung has1184 The Journal of Thoracic and Cardiovascular Ssome anatomic characteristics. The left main bronchus is longer
than the right main bronchus. That means more vulnerability to tu-
berculosis bacilli. So that’s why a left-sided pneumonectomy is
more often done than a right-sided pneumonectomy.
Dr Pomerantz.Well, I’m not sure that’s right. I’m not sure what
the answer is either, but it’s possibly due to the upper and lower
lobe bronchial takeoff being so close together. That’s another op-
tion. No one has been able to give me a good explanation. You
have a higher number of segmental resections than we had in our
series. I always thought it was better to make a wider resection
than just a segmental. We had several, but not the higher percent-
ages you have.
Dr Shiraishi. We performed a segmentectomy only in patients
with very tiny cavities or tiny nodular lesions. We usually do lobec-
tomy because the cavity is bigger. So in our series, the patients who
had a segmentectomy had very limited lesions.
Dr Pomerantz.My final question is, you had 2 bronchopleural
fistulas. Were they in patients who had positive sputum at the time
of surgery, and were they on the right side or the left?
Dr Shiraishi. If I recall correctly, one bronchopleural fistula oc-
curred on the right side after pneumonectomy. The other broncho-
pleural fistula occurred after left upper lobectomy. Both patients
had positive sputum at the time of surgery and comorbidities,
such as diabetes. Those patients had bronchopleural fistula 1 or 2
years after surgery, and the bronchial stump was eroded by the re-
lapse of multidrug-resistant strains, and that caused bronchopleural
fistula.
Dr Nasser Altorki (New York, NY). I want to ask you a little bit
about the segmentectomy. Are you advocating that patients with
MDR-TB have a lobectomy even if anatomically a segment can
be performed?
Dr Shiraishi. It depends on the patient’s pulmonary functional
reserve.
Dr Altorki. Assuming that the pulmonary examination allows
you to do either of these operations, is a segmentectomy sufficient
if you can get rid of gross disease, or do you have microscopic dis-
ease that requires a lobectomy be preferred?
Dr Shiraishi.We performed segmentectomy mostly on the left
upper division or lingular. In patients with limited lesions, we can
take whole lesions by performing a segmentectomy, not a lobec-
tomy.
Dr Altorki. I ask because the seminal work by Churchill and
Belsey described segmentectomy exactly in patients with tubercu-
losis, and I wonder if the fact that they have drug-resistant tubercu-
losis changes the treatment at all.
Dr Shiraishi. No, it won’t.
Dr Altorki. Thank you for your answer.urgery c November 2009
